Ataraxis AI lands $20.4M Series A to cut unnecessary chemo
What's the deal? Ataraxis AIDealroom has a profile for this one. Try Dealroom →, a New York-based startup using artificial intelligence to guide cancer treatment, has raised a $20.4 million Series A. AIX VenturesDealroom has a profile for this one. Try Dealroom → led the round, with Thiel BioDealroom has a profile for this one. Try Dealroom →, Founders Fund, Floating PointDealroom has a profile for this one. Try Dealroom →, BertelsmannDealroom has a profile for this one. Try Dealroom →, and existing backers Giant VenturesDealroom has a profile for this one. Try Dealroom → and Obvious Ventures participating.
What's the endgame? The company wants to predict long-term cancer outcomes to determine whether aggressive treatments like chemotherapy are necessary — potentially sparing patients its severe side effects. It has commercially launched its first breast cancer test and plans to expand into other cancers.
How it works: Ataraxis AI's model analyses high-resolution images of cancer cells and was trained on hundreds of millions of images from thousands of patients. A recent study found the technology is 30% more accurate than the current standard for breast cancer care, according to the company.
Why now? Most AI-driven cancer tools focus on early detection; Ataraxis targets treatment decisions instead. The startup emerged from stealth in 2025 and had previously raised a $4 million seed round.
The company was co-founded by Jan Witowski and Krzysztof Geras, an assistant professor at New York University's medical school specialising in AI. Meta's chief AI scientist, Yann LeCun, serves as an AI adviser. Ataraxis positions itself as a frontier AI company focused on healthcare and aims for its tests to influence half of all new cancer cases by 2030.
By the numbers: The round sits in the roughly 52nd percentile for deal size — a solid but middle-of-the-pack Series A, reflecting steady rather than outsized investor conviction.
The signal: The raise lands amid a broader surge of investment in AI-driven cancer care. Valar LabsDealroom has a profile for this one. Try Dealroom → raised $22 million in May 2024 to help patients plan treatment, and Manas AI, co-founded by LinkedIn's Reid Hoffman, secured $24.6 million for AI drug discovery in January 2025 — evidence that capital is flowing into applying AI across the cancer care chain.
Read more: Newzchain
Image credit: Generated with Gemini
